Speaker
JEE HYANG JEONG
(EWHA Womans University Seoul Hospital)
Summary
In this real-world cohort, lecanemab was associated with a large 6-month reduction in amyloid-PET Centiloid (≈−29 CL), consistent with robust target engagement. Cognitive measures were overall stable to slightly worsened over 6 months, a time frame that may be too short to detect clinical benefit despite substantial amyloid clearance. Exploratory analyses suggested numerically greater Centiloid reductions among APOE ε4 carriers and those with MCI, but differences were not statistically significant. Larger, longer follow-up is warranted to relate biomarker changes to clinical trajectories.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
Author
JEE HYANG JEONG
(EWHA Womans University Seoul Hospital)
Co-author
Keon Wook Kang
(Seoul National University College of Medicine)
